Boston Scientific Corporation
BSX · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $131,434 | $83,998 | $66,189 | $60,419 |
| - Cash | $414 | $865 | $928 | $1,925 |
| + Debt | $11,147 | $9,492 | $9,282 | $9,451 |
| Enterprise Value | $142,167 | $92,625 | $74,543 | $67,945 |
| Revenue | $16,747 | $14,240 | $12,682 | $11,888 |
| % Growth | 17.6% | 12.3% | 6.7% | – |
| Gross Profit | $10,267 | $8,831 | $7,714 | $7,461 |
| % Margin | 61.3% | 62% | 60.8% | 62.8% |
| EBITDA | $3,938 | $3,453 | $2,741 | $2,518 |
| % Margin | 23.5% | 24.2% | 21.6% | 21.2% |
| Net Income | $1,854 | $1,593 | $698 | $1,040 |
| % Margin | 11.1% | 11.2% | 5.5% | 8.7% |
| EPS Diluted | 1.25 | 1.073 | 0.446 | 0.687 |
| % Growth | 16.5% | 140.6% | -35.1% | – |
| Operating Cash Flow | $3,435 | $2,503 | $1,526 | $1,870 |
| Capital Expenditures | -$790 | -$800 | -$612 | -$554 |
| Free Cash Flow | $2,645 | $1,703 | $914 | $1,316 |